UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Minutes of the 2026 Annual General Shareholders' Meeting

Meeting Format:

Hybrid shareholders' meeting (meeting convened physically, supplemented by video conference)

Time: 9:00 a.m. on May 28, 2026 (Thursday)

Physical shareholders' meeting venue:

4F, G Building, No. 3-1, Yuanqu St., Nangang District, Taipei City

Video conference platform:

Taiwan Depository & Clearing Corporation "Stock Services Platform" – eMeeting platform (URL: https://stockservices.tdcc.com.tw)

Countermeasures for postponing or reconvening the meeting if the Platform or participation in the virtual meeting is obstructed due to natural disasters, accidents or other force majeure events: Please refer to the meeting notice for details; there were no such obstructions to the platform during this meeting.

Attendance:

The number of shares represented by shareholders attending the meeting in person or by proxy was 46,920,213 shares, which accounted for 55.37% of the 84,724,899 shares issued by the Company.

Chairperson: Shu-Fang Ou, Chairperson of the Board of Directors

Recorder: Yu-Chiao Sun

Attending directors:

Director Pi-Jung Lin, Director Tsan-Der Chou, Director Su-Hei Weng, Independent Director Min-Zhi Xiao (Convener of the Audit Committee), Independent Director Vincent Liu, and Independent Director Yun-Hua Yang attended the meeting in person, while Independent Director Wei-Ju Chen attended via video conference. The directors in attendance represented more than half of the Company's nine board seats.

Other Attendees:

General Manager Kenneth Lu, Finance and Accounting Director Yu-Chiao Sun, CPA of Deloitte & Touche Tsung-Yuan Tsai and Attorney of ERIK International Law Office Tung-Yuan Chiang.

I. 【**Announcement of the Commencement of the Meeting**】The aggregate shareholding of the shareholders present in person or by proxy constituted a quorum. The Chairperson called the meeting to order.

II. 【**Chairperson's Address**】(Omitted)

III. 【**Matters to be Reported**】

1. The 2025 business report is submitted for your review. Please refer to Appendix 1.

2. The 2025 financial statements report reviewed by the Audit Committee is submitted for your review. Please refer to Appendix 2.

3. The report on the distribution status of 2025 employee compensation and director remuneration is submitted for your review.

Description:

The distribution amount of employee compensation was NT$41,457,043, and the distribution amount of director remuneration was NT$16,000,521, accounting for 3.00% and 1.16%, respectively, of the profit before tax and before distribution deduction of employee and director remuneration, both of which were paid in cash and were not different from the estimated amounts recorded in the accounts.

Of the aforementioned employee compensation, 30% was distributed to non-executive employees, for an amount of NT$12,437,113 distributed.

4. The report on the distribution status of 2025 cash dividends is submitted for your review.

Description:

As approved by the Board of Directors on March 5, 2026, the Company distributed cash dividends to shareholders in the amount of NT$656,617,968 out of the distributable earnings for the year 2025, with each share being distributed with a dividend of NT$7.75, distributed on April 22, 2026.

5. The report on the investment status in Mainland China is submitted for your review. Please refer to the Proceedings Manual of the Meeting.

6. The report on the status of undertaking the endorsement and guarantee is submitted for your review.

Description:

As of March 31, 2026, the status of the endorsement and guarantee the Company provided to the subsidiaries in accordance with the "Procedures for Endorsement and Guarantee" is set out in the table below.

No.	Guarantee	Relationship to this Company	Financing institution	Guaranteed amount		Actual amount borrowed	
				Currency	Amount (thousand)	Currency	Amount (thousand)
1	Kunshan Universal Trading Co., Ltd.	70% owned subsidiary of the Company	Bank SinoPac	USD	3,000	USD	-

Note: The above amount does not exceed the specified limit.

7. The report on the Company's 2025 director remuneration is submitted for your review.

Description:

(1) The relationships between the distribution policy, standard and combination, and procedures for the remuneration of the Company with business performance and future risks:

I. Article 25-1 of the Company's Articles of Incorporation authorizes the Board of Directors to determine director remuneration according to the level of each director's participation in the operation and the value of their contribution, and take into account the domestic standards of the same trade. Additionally, in accordance with Article 30 of the Articles of Incorporation, if there are any remaining profits in the prevailing year, no more than 3% of the prevailing year's profits may be distributed as director remuneration.

II. Director remuneration is regularly evaluated in accordance with the Rules for Performance Evaluation of Board of Directors. The major evaluation items are comprehensively considered for director remuneration as follows:

i. Business performance: Comprehensively references factors from this year including the 4% growth of the operating revenue and the pre-tax net profits remaining flat.

ii. Annual rating: References the Company being ranked among the top 5% of TPEx-listed companies in the Corporate Governance Evaluation, and the results of Board of Directors and functional committee annual performance evaluations, all of which were remarkably outstanding.

iii. Peer level: References the average level of director remuneration provided by the peer TPEx-listed Companies.

III. The director remuneration for this year accounts for 2.35% of net profit after tax. The actual amount of director remuneration paid this year was reviewed by the Compensation Committee and then resolved upon by the Board of Directors.

IV. The distribution policy for the director remuneration of the Company is positively related to the operating performance and future risks. The rationality of director remuneration is regularly evaluated by both the Compensation Committee and the Board of Directors. In addition to considering individual directors' individual responsibilities and contributions, the Company's overall operating performance, industrial development trends and future risks are also considered as the criteria for determining the payment; the remuneration system is also reviewed in a timely manner in accordance with relevant laws and regulations to improve the efficiency of the board's operations.

(2) The details of the individual director remuneration are shown on the following page:

Unit: Thousand NT$

Position	Name	Remuneration to Directors								The sum of A, B, C and D and proportion to net profit after tax		Remuneration to the capacity as employees								The sum of A, B, C, D, E, F and G and proportion to net profit after tax		Remuneration received from an invested company other than the company's subsidiary or parent company
		Remuneration (A)		Pension (B)		Remuneration to directors (C) (Note 1)		Business execution expenses (D)				Salaries, bonus and special disbursement(E)		Pension (F)		Remuneration to employees (G)						
		The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company		All companies mentioned in the financial statements		The Company	All companies mentioned in the financial statements	
																Cash	Stock	Cash	Stock			
Chairperson	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang	2,184	2,184	-	-	2,311	2,311	50	50	4,545 0.44%	4,545 0.44%	-	-	-	-	-	-	-	-	4,545 0.44%	4,545 0.44%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	962	962	58	58	-	-	-	-	3,381 0.32%	3,381 0.32%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen	-	-	-	-	2,311	2,311	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Xiao Min-Zhi	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Liu Vincent	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Yang Yun-Hua	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None
Independent Director	Chen Wei-Ru	1,200	1,200	-	-	1,111	1,111	50	50	2,361 0.23%	2,361 0.23%	-	-	-	-	-	-	-	-	2,361 0.23%	2,361 0.23%	None

Note 1: The 2025 director remuneration was an estimate.

IV.【Matters for Acknowledgment】

Agenda 1 (proposed by the Board of Directors)

Proposal: The 2025 business report and financial statements are submitted for acknowledgment.

Description:

1. The audit of the Company's 2025 financial statements and consolidated financial statements has been completed by the certified public accountant Liao Wan-I and the certified public accountant Tsai Tsung-Yuan from Deloitte & Touche, and a written audit report has been issued.
2. For the 2025 business report, certified public accountant's audit report, and the aforementioned financial statements, please refer to Appendix 1 and Appendixes 3-4.
3. Please acknowledge the proposal.

Resolution: The voting results were as follows:

Shares present at the time of voting: 46,920,213

Voting Results	% of the total shares present
Votes in favor: 46,235,361 (Electronic votes: 4,831,765 ; Virtual votes: 0)	98.54%
Votes against: 74,276 (Electronic votes: 74,276 ; Virtual votes: 0)	0.15%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained / Not Voted: 610,576 (Electronic votes: 585,876 ; Virtual votes: 3,000)	1.30%

The proposal was approved after voting.

Agenda 2 (proposed by the Board of Directors)

Proposal: The 2025 Statement of the Distribution of Earnings is submitted for acknowledgment.

Description:

1. The review of the Company's 2025 Statement of the Distribution of Earnings had been completed by the Audit Committee and submitted to the Board of Directors for approval.
2. For the 2025 Statement of the Distribution of Earnings, please refer to Appendix 5.
3. Please acknowledge the proposal.

Resolution: The voting results were as follows:

Shares present at the time of voting: 46,920,213

Voting Results	% of the total shares present
Votes in favor: 46,245,241 (Electronic votes: 4,841,645 ; Virtual votes: 0)	98.56%
Votes against: 78,064 (Electronic votes: 78,064 ; Virtual votes: 0)	0.16%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained / Not Voted: 596,908 (Electronic votes: 572,208 ; Virtual votes: 3,000)	1.27%

The proposal was approved after voting.

Shareholder’s Question (Account No. 00080529):

Good morning, Chairperson and General Manager. I would like to inquire about the Company’s recent acquisition of approximately 92,000 shares of TSMC at a cost of approximately NT$207 million, bringing its total holdings to 387,000 shares. Was this investment made primarily for long-term capital allocation, short-term financial operations, or based on the Company’s assessment of industry prospects? Does the Company have any limits on securities investments, as well as risk management and Board oversight mechanisms? Going forward, how will the Company balance capital utilization among investments in its core business, shareholder returns, and financial asset investments?

Response (Summary) by Yu-Chiao Sun, Director of Finance and Accounting, as designated by the Chairperson:

This investment was made as part of the Company’s long-term capital allocation strategy rather than for short-term financial operations. Accordingly, the investment is recognized under equity rather than through profit or loss in the financial statements and therefore will not cause fluctuations in the Company's earnings. With respect to industry outlook, the investment was made in consideration of the current AI development trend and TSMC’s strong competitive advantages and earnings growth potential, which provide a significant “economic moat.” All of the Company’s securities investments are conducted in accordance with its Procedures for Acquisition or Disposal of Assets, as well as established internal control procedures. As for balancing future capital utilization among investments in the Company’s core business, shareholder returns, and financial asset investments, the Company will continue to monitor market conditions and its actual fund position before making investment decisions.

V. 【Extraordinary Motions】 None.

VI. 【Adjournment】 9:23 a.m., Thursday, May 28, 2026.

Appendix 1

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
2025 Business Report

1. Operating Status in 2025

(1) Operating results:

The Group's consolidated operating revenue in 2025 was NT$4,204,086 thousand, a decrease of 0.57% over the previous year; consolidated net profit attributable to the Company's owners of the parent was NT$1,042,637 thousand, a decrease of NT$22,084 thousand, or 2.07% over the previous year.

The independent operating revenue of the parent company in Taiwan was NT$3,649,649 thousand in 2025, an increase of 3.88% over the previous year, and the parent company's operating revenue accounted for 86.81% of the Group's consolidated operating revenue. In Taiwan (including Penghu), there were 34 self-owned eyewear stores, contributing sales revenue of NT$952,943 thousand, making up 26.11% of the total operating revenue and representing a year-on-year increase of 13.34%. With a total of 31 partner clinics, the income generated from brand licensing, technical services, consulting, and rental to the clinics was NT$2,128,196 thousand, accounting for 58.31% of the total operating revenue and representing a year-on-year decrease of 3.37%. The income from medical supplies was NT$568,510 thousand, accounting for 15.58% of the total operating revenue and representing a year-on-year increase of 20.92%.

(2) Budget implementation status:

The Company's internal budget for the year 2025 had been approved by the Board of Directors, but the financial forecast has not been disclosed to the public. The overall operating condition was good.

(3) Profitability analysis:

Unit: Thousand NT$

Item / Year		2025	2024
Financial revenue and expenditure	Net consolidated operating revenue	4,204,086	4,228,302
	Consolidated gross profit	2,482,587	2,533,286
	Consolidated net profit attributable to owners of the parent	1,042,637	1,064,721
Profitability	Consolidated return on assets (%)	18.13	19.59
	Consolidated return on shareholders' equity (%)	26.65	29.59
	Consolidated gross margin (%)	25.09	24.84
	Consolidated earnings per share (NT$)	12.31	12.57

(4) Research and development status:

In recent years, the Company has continued to introduce advanced ophthalmic technologies and equipment, including femtosecond laser assisted cataract surgery and SMILE Pro, the next-generation of SMILE Laser Vision Correction. In 2024, the Company further introduced SMILE Pro 2.0, featuring an enhanced AI tracking function, along with a new type of intraocular lens designed to minimize glare. In 2025, the Company further introduced the EVO implantable collamer lens (EVO ICL) technology. This is a vision correction solution for people who have advanced nearsightedness, but who lack sufficient corneal thickness for LASIK. The technology has a market history of 30 years, and more than 3,000,000 corrections have been performed worldwide. The Company has introduced the new implantable lens with central hole (Hole ICL) technology. In addition, the Company has supported its partner clinics by providing training and implementation programs related to these new technologies, which have been highly praised by partner clinics' medical teams. Such efforts have significantly optimized surgical efficiency and service quality, offering partner clinics more advanced medical options and enhancing the overall brand reputation through positive word-of-mouth recognition.

Furthermore, adhering to the business philosophy of providing high-quality products to the public, the Company established a cross-disciplinary team integrating biotechnology and food science to jointly develop "Universal Gold Lutein", an eye nutrition supplement suitable for the entire family. The raw materials and manufacturing processes are subject to strict quality control, with formulations specifically tailored to meet the nutritional needs of seniors, adults, and children. In response to the demands of modern digital lifestyles, the Company launched a new "SOS Enhanced" formula, offering comprehensive solutions for maintaining visual clarity and moisture. Since its launch, "Universal Gold Lutein" has received numerous prestigious awards, including the "SNQ Award", "National Biotechnology and Medical Care Quality Award", "National Brand Yushan Award", "Taiwan Excellent Manufacturer Award", "National Biotechnology Award", "Monde Selection Gold Quality Award", and "iTQi Superior Taste Award". These accolades highlight the Company's unwavering commitment to quality and dedication to safeguarding public health.

2. Summary of Business Plan for 2026

(1) Management Policy and Operation Objectives

A. Ophthalmology market

(a) Refractive correction market

The refractive correction market has experienced rapid growth in recent years, with increasing acceptance among the general public. At the end of 2022, the Company introduced SMILE Pro, the next-generation laser vision correction surgery, which features a minimally invasive procedure that reduces dry-eye symptoms while offering enhanced comfort, speed, and safety. This technology has helped partner clinics provide their customers with comprehensive and high-quality vision correction solutions. In 2025, the Company also introduced EVO implantable collamer lens (ICL) technology, which is the only vision correction solution other than eyeglasses for people who have advanced nearsightedness but lack sufficient corneal thickness for LASIK. In the first quarter of 2026, the Company is also introducing SMILE Pro 3.0 Max. Built on the Zeiss SMILE Pro platform, this solution integrates big data AI software developed through 130,000 surgeries at partner clinics. The platform first correlates a variety of patient exam data; then, with consideration given to patients' eye usage needs and habits, the platform plots out surgery parameters and provides surgeons with a basis for reference during the treatment process. The platform thus serves as a strategy for differentiation in the highly-competitive laser vision correction market. In addition to existing refractive laser technologies, the Company has also introduced and developed PresbyLASIK and myopia laser technology equipment for its partner clinics to address the increasing demand from the presbyopic population.

(b) Cataract market

The Company has continued to support its partner clinics in promoting advanced technologies and applications for femtosecond laser-assisted cataract surgery combined with premium intraocular lens (IOL) selections. This approach offers the advantages of precision medicine and superior post-operative visual outcomes, assisting partner clinics in continuously increasing the adoption rate of the femtosecond laser-assisted cataract procedure. In addition, the Company has introduced a new type of intraocular lens featuring reduced glare and extended depth of focus, further enhancing patient satisfaction with cataract surgery.

(c) Dry-eye treatment market

Demand in the dry eye treatment market is substantial, as many contact lens users, middle-aged individuals, and seniors require ongoing care. Moreover, continuous dry eye management is often necessary following laser vision correction and cataract surgeries. Since 2022, the Company has gradually introduced the dry eye treatment program and equipment into its partner clinics, and patient acceptance has steadily increased over the past two years. It is anticipated that, as patient satisfaction continues to spread through word of mouth, the service volume will grow progressively in the coming years.

B. Optometry market

(a) Innovative technology and precise services: The e-Universal brand leading the Optometry Sector

Leveraging innovative technology, the Company launched "i-Precision Intelligent Prescription", which integrates 21 examination steps and 21 myopia management measures. By implementing the core philosophy of "Medical Optometry, Scientific Eyewear Prescription" throughout this process, the Company creates prescriptions that offer a high degree of expertise and reproducibility. The Company has taken the lead by deploying multi-focal, stress-relief real lens experience equipment from Japan's Hoya and France's Essilor across all stores. With this equipment, optometrists can guide customers through a real experience of different lenses' clarity, comfort, and dynamic visual performance. This helps customers get a clear sense of the real benefits that each optical design brings.

The Company has also continued to optimize in the multi-focal experience domain by creating the Smart Multi-Focal Real Lens Experience. Using scenario-based design, this helps customers experience switching between far, middle, and near vision in environments that approximate real life. This gives them a clear sense of the smoothness and stability of different lenses' fields of view. The Company is also adding in Essilor's newest EyeRuler 2 precision application, which combines expert optometric personnel and technology with AI computing, to make sure that every lens is highly personalized and precisely prescribed.

In the smart eyeglass applications field, in addition to offering diverse eyeglass prescription choices, the Company is also introducing optical waveguide prescription lens prescription technology. This will create next-level flexibility for future smart vision applications; make for integrated prescription solutions equipped with both forward-looking technology and practical value; and put the Company's overall service even further ahead of existing prescription modes on the market, in terms of expertise, fashionability, and technical advancement.

Looking to the future, the Company will continue to strengthen its offerings in myopia control products; senior vision service packages; lutein and other eye health supplements; and personalized value-added product services. Through systematic product strategies and enhanced experiences, the Company will drive steady growth in both revenue and profitability, while building the competitive edge that will enable long-term expansion.

(b) Big Vision Project: Comprehensive eye health management

By integrating the technological strengths and equipment of partner clinics with the Company's self-operated optical stores, the Company actively promotes systematic management for myopia control and axial length tracking among school-age children. Through technological innovation and AI applications, the Company continues to introduce advanced optometry equipment and continues introducing a diverse range of myopia control products, thus strengthening vision care engagement and long-term retention for students and their parents.

Centered around the philosophy of "Lifelong Eye Health Solutions for the Entire Family," the Company has integrated optometry services, myopia prevention and control, and related vision health solutions under the e-Universal brand. By creating a vision health model for continuous tracking and management, the Company has become customers' reliable partner at every stage of life. This integrated strategy not only strengthens the brand's market value, but also delivers comprehensive, stable, and reliable eye health solutions to an expanding consumer base.

(2) Important production and marketing strategies

A. Marketing strategy

The Company actively establishes long-term strategic partnerships with major optical and biotechnology corporations, both domestically and internationally, to integrate R&D, product, and marketing resources, and thus to jointly drive innovation and application in optical products and technologies. Concurrently, the Company continues to invite partner clinics to participate in vision care and public welfare-promotion initiatives, integrating professional services with corporate social responsibility. Through these efforts, the Company promotes public awareness of vision health and hygiene, thereby naturally cultivating good habits for healthy eye care among the public, while also building brand trust and a long-term customer base.

B. Brand strategy

Centering on the “e-Universal” brand, the Company integrates Taiwan’s leading ophthalmic medical and optometric services to build a one-stop solution for vision health, based on Medical Optometry and Dual-Expert Precision, thus providing comprehensive, integrated solutions. To further enhance the customer experience, the Company has launched an exclusive e-commerce platform for prescription eyewear and eye care products, achieving seamless integration between online and offline services. This not only expands online points of contact, but also guides traffic to physical stores, thus enhancing both overall service efficiency and the customer experience.

To achieve long-term development objectives, the Company continues to optimize its operational capabilities and enhance the per-store productivity of its existing locations. Additionally, by leveraging the channel resources of partner clinics and implementing cross-marketing strategies, the Company is comprehensively strengthening its brand impact. Through continuous innovation and professional excellence, the Company is committed to leading the market and achieving its goal of becoming the leading brand in Taiwan’s vision optics industry.

(3) Impact of external competitive environment, regulatory environment, and overall business environment

While pursuing stable growth and enhanced operating efficiency, the Company also continues to systematically integrate ESG sustainable development into the corporate governance structure, operating strategies, and day-to-day management. Through systematic, concrete action, the Company is strengthening corporate resilience to create corporate value that is both long-term and sustainable.

Looking at corporate governance, in the 11th Corporate Governance Evaluation in 2025, the Company was ranked among the “Top 5% of TPEx-listed Companies” for a third straight year; and received the highest honor as a “Top 10% of Non-financial/electronic TWSE/TPEx-listed Companies with a Market Value of NT$10 Billion or Above” for a second time. This highlights the Company’s outstanding performance in the four aspects of protecting shareholder rights and interests, board of directors' operations, information transparency, and sustainable development. This year, the Company maintained its AA rating in the Morgan Stanley Capital International (MSCI) ESG Ratings. This represents one of the highest ratings among all listed companies, and makes the Company a standout among biotech stocks. These achievements make clear the Company's outstanding performance in both sustainable governance and risk management, and have won the Company high praise in international capital markets.

In continued response to rapid changes in the external competitive environment and legal requirements, the Company also launched many governance and sustainability reinforcement measures for the first time in 2025. The Corporate Value Enhancement Plan has been formulated and submitted to the board of directors, to serve as the major guidance for medium- and long-term operations and capital allocations. In addition, this year's in-person general shareholders meeting will adopt a simultaneous hybrid shareholders meeting mechanism. This will enhance shareholder participation and promote corporate governance. Also, in the event of disaster or other force majeure circumstances, such flexible participation options will help ensure that shareholder rights and interests remain unaffected.

Turning to environmental and climate risks, in 2025, the Company formally formulated its Environmental Management System and its Energy Management Plan. These will continue to strengthen the efficiency of energy usage and environmental management performance. Assessing the potential effects of climate change on the Company's finances and operations in a quantified way will serve as a major reference for future operational decision-making and risk management.

In terms of the social aspect, the Company is concerned with talent cultivation, care for employees, and protecting customers' rights and interests. The Company has formulated an Employment Training and Development Plan, aimed at enhancing employee career capacity; and the Company periodically holds Employee Satisfaction Surveys, in order to continuously optimize the working environment, enhance employee cohesion, and increase overall organizational efficiency. In addition, the Company has established a Personal Data Protection Policy, and with relation to topics such as the health and security of customers for products and services, marketing and labeling, etc., the Company has put in place a consumer protection policy and a complaint mechanism. These help ensure that customers' rights and interests receive appropriate protections.

Looking at continuous improvement for governance structures, the Company established the board of directors-level Sustainable Development Committee in 2025. This committee is responsible for overseeing the corporate sustainability strategy, policy formulation, and implementation status. This further strengthens the board of directors' oversight and strategy functions with regard to sustainability topics.

The Company will continue to respond to the changes in the external competitive environment, legal systems, and the overall operating environment. The Company will deepen the foundation for ESG governance, and strengthen its operating resilience and sustainable competitive advantages, in order to build long-term value for shareholders, employees, customers, and society as a whole, with stable operations as the core.

(4) Future Development Strategy

Universal Vision Biotechnology Co., Ltd. (“UVB”) upholds the corporate philosophy inspired by the “Great Learning”—to manifest one’s bright virtue, to love the people, and to pursue the highest good. UVB will continue to firmly advance long-term development for the eye care industry, with expert medical care as the core. The Company will continue to introduce advanced medical technologies and equipment that possess clinical value and market competitiveness. Through systematic training and operational support, the Company will help partner clinics enhance their quality of medical care, surgical efficiency, and overall customer satisfaction. All of this will help to further consolidate the Company’s trusted reputation for medical expertise.

In terms of optometric services, UVB is integrating resources from the Company’s self-operated optical stores and partner clinics, to deepen the “Medical Optometry, Scientific Eyewear Prescription” service model. By continuing to develop prescription processes and product service experiences with both high standards and strong reproducibility, UVB is providing consumers with eye health solutions that are more precise, more personalized, and hold greater long-term value. This is enhancing the customer’s life-long service experience.

Going forward, UVB will use platform-based thinking to continue expanding service channels and operating models. UVB will integrate medical ophthalmology, optometric services, and eye health products to build an eye health ecosystem for the customer’s entire lifespan, thus responding to long-term trends toward changes in the population structure and increasing market demand. The Company will continue to strengthen operational resilience and organizational efficiency, to maintain stable growth momentum. By moving toward the corporate vision of “See Clear, See Comfort, See the Future!”, we will continue doing our utmost to be the primary force driving continued enhancement of Taiwan’s eye health industry; and by doing this, we will create long-term, sustainable value for shareholders, customers, and society as a whole.

Chairperson: Ou Shu-Fang

General Manager: Lu Kenneth

Accounting Manager: Sun Yu-Chiao

Appendix 2

Audit Committee Review Report

The 2025 business report, financial statements (including parent company only financial statements and consolidated financial statements), the earnings distribution proposal, etc., among which the audit of the financial statements has been completed by the certified public accountants Liao Wan-I and Tsai Tsung-Yuan from Deloitte & Touche Accounting Firm, who also issued the audit report. The review of the aforementioned business report, financial statements and earnings distribution statement has been completed by the Audit Committee, which believes that there is no inconsistency. This report is hereby made in accordance with the provisions of Article 14-4 of the Securities and Exchange Act as well as Article 219 of the Company Act, and is submitted for your review.

Submitted to

2026 General Shareholders' Meeting of Universal Vision Biotechnology Co., Ltd.

Convener of Audit Committee: Xiao Min-Zhi

March 5, 2026

Appendix 3

INDEPENDENT AUDITORS' REPORT

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Opinion

We have audited the accompanying parent company only financial statements of Universal Vision Biotechnology Co., Ltd. (the "Company"), which comprise the parent company only balance sheets as of December 31, 2025 and 2024, and the parent company only statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the parent company only financial statements, including material accounting policy information (collectively referred to as the " parent company only financial statements").

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2025 and 2024, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter for the Company's financial statements for the year ended December 31, 2025 is described as follows:

Ophthalmology Business Division - Occurrence of Technical Service Revenue

The Company's ophthalmology business division 2025 operating revenue - technical service revenue is the main revenue and is growing year by year, which has a significant impact on independent financial statements; thus, we listed the occurrence of ophthalmology business division - technical service revenue as a key audit matter. For additional information on the accounting policy of revenue recognition, refer to Note 4.m. to the financial statements.

We have performed principal audit procedures for confirming the occurrence of the ophthalmology business division - technical service revenue as below:

1. We obtained an understanding of the design and tested the implementation effectiveness of internal control of the ophthalmology business division - technical service revenue.

2. We obtained the subsidiary ledger of the ophthalmology business division - technical service revenue and examined the contents, checked the contracts, relevant supporting documents and the collection of receivables to confirm the authenticity of the recognized technical service revenue.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors’ report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision, and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors’ report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Wan-I Liao and Tsung-Yuan Tsai.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 5, 2026

<u>*Notice to Readers*</u>

The accompanying parent company only financial statements are intended only to present the financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying parent company only financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and parent company only financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025		2024	
ASSETS	**Amount**	**%**	**Amount**	**%**
CURRENT ASSETS				
Cash and cash equivalents (Notes 4 and 6)	$ 327,557	6	$ 93,414	2
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	1,233,479	21	1,295,373	24
Financial assets at amortized cost - current (Notes 4, 9 and 10)	-	-	24,000	-
Trade receivables (Notes 4, 11 and 23)	478,634	8	506,811	9
Trade receivables from related parties (Notes 4, 11 and 30)	5,997	-	7,189	-
Other receivables (Note 30)	6,731	-	9,255	-
Inventories (Notes 4 and 12)	263,815	5	255,774	5
Other current assets	51,969	1	35,107	1
Total current assets	2,368,182	41	2,226,923	41
NON-CURRENT ASSETS				
Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10)	108,744	2	111,073	2
Investments accounted for using the equity method (Notes 4 and 13)	499,035	8	527,848	10
Property, plant and equipment (Notes 4, 14 and 31)	1,778,658	31	1,578,576	29
Right-of-use assets (Notes 4 and 15)	877,410	15	858,064	16
Intangible assets (Notes 4 and 16)	3,693	-	4,263	-
Deferred tax assets (Notes 4 and 25)	61,327	1	54,990	1
Prepayments for equipment	36,885	1	-	-
Refundable deposits	35,117	1	33,085	1
Total non-current assets	3,400,869	59	3,167,899	59
TOTAL	$ 5,769,051	100	$ 5,394,822	100
LIABILITIES AND EQUITY				
CURRENT LIABILITIES				
Short-term borrowings (Notes 17 and 31)	$ 50,000	1	$ 50,000	1
Trade payables (Note 18)	187,904	3	225,754	4
Payables for equipment (Note 20)	81,439	1	90,614	2
Other payables (Note 19)	219,238	4	228,258	4
Current tax liabilities (Notes 4 and 25)	140,658	2	143,900	3
Lease liabilities - current (Notes 4 and 15)	155,836	3	143,982	3
Other current liabilities (Note 23)	33,909	1	21,052	-
Total current liabilities	868,984	15	903,560	17
NON-CURRENT LIABILITIES				
Deferred tax liabilities (Notes 4 and 25)	50,846	1	47,053	1
Lease liabilities - non-current (Notes 4 and 15)	767,842	13	750,713	14
Long-term accounts payable (Note 20)	57,781	1	70,908	1
Guarantee deposits	575	-	575	-
Total non-current liabilities	877,044	15	869,249	16
Total liabilities	1,746,028	30	1,772,809	33
EQUITY (Note 22)				
Share capital				
Ordinary shares	847,249	15	847,249	16
Capital surplus	381,924	7	381,924	7
Retained earnings				
Legal reserve	480,779	8	378,623	7
Special reserve	-	-	11,384	-
Unappropriated earnings	2,314,256	40	1,998,328	37
Total retained earnings	2,795,035	48	2,388,335	44
Other equity	(1,185)	-	4,505	-
Total equity	4,023,023	70	3,622,013	67
TOTAL	$ 5,769,051	100	$ 5,394,822	100

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024	
	Amount	**%**	**Amount**	**%**
OPERATING REVENUE (Notes 4, 23 and 30)	$ 3,649,649	100	$ 3,513,460	100
OPERATING COSTS (Notes 12 and 24)	(1,474,950)	(40)	(1,361,200)	(39)
GROSS PROFIT	2,174,699	60	2,152,260	61
OPERATING EXPENSES (Notes 11, 21 and 24)				
Selling and marketing expenses	(485,388)	(14)	(433,851)	(12)
General and administrative expenses	(325,055)	(9)	(302,812)	(9)
Expected credit gain	19	-	-	-
Total operating expenses	(810,424)	(23)	(736,663)	(21)
PROFIT FROM OPERATIONS	1,364,275	37	1,415,597	40
NON-OPERATING INCOME AND EXPENSES (Notes 4, 24 and 30)				
Interest income	62,533	2	36,248	1
Other income	6,051	-	7,263	-
Other gains and losses	(67,640)	(2)	(97,333)	(3)
Finance costs	(21,394)	(1)	(15,697)	-
Share of loss of subsidiaries, associates and joint ventures	(19,381)	-	(27,339)	(1)
Total non-operating income and expenses	(39,831)	(1)	(96,858)	(3)
PROFIT BEFORE INCOME TAX	1,324,444	36	1,318,739	37
INCOME TAX EXPENSE (Notes 4 and 25)	(281,807)	(8)	(254,018)	(7)
NET PROFIT FOR THE YEAR	1,042,637	28	1,064,721	30
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 4, 22 and 25)				
Items that will not be reclassified subsequently to profit or loss:				
Unrealized gain on investments in equity instruments designated as at fair value through other comprehensive income	702	-	-	-
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation of the financial statements of foreign operations	(8,932)	-	23,420	1
Unrealized gain (loss) on investments in debt instruments at fair value through other comprehensive income	942	-	(3,559)	-
Income tax relating to items that may be reclassified subsequently to profit or loss	1,598	-	(3,972)	-
Other comprehensive income (loss) for the year, net of income tax	(5,690)	-	15,889	1
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	$ 1,036,947	28	$ 1,080,610	31
EARNINGS PER SHARE (Note 26)				
Basic	$ 12.31		$ 12.57	
Diluted	$ 12.26		$ 12.53	

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	Share Capital			Retained Earnings			Other Equity		
	Shares (In Thousands)	Amount	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of the Financial Statements of Foreign Operations	Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	Total Equity
BALANCE ON JANUARY 1, 2024	84,725	$ 847,249	$ 381,924	$ 278,614	$ 5,042	$ 1,676,197	$ (11,384)	$ -	$ 3,177,642
Appropriation of 2023 earnings									
Legal reserve	-	-	-	100,009	-	(100,009)	-	-	-
Special reserve	-	-	-	-	6,342	(6,342)	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(593,074)	-	-	(593,074)
Changes in the Company's ownership interests in subsidiaries (Note 13)	-	-	-	-	-	(43,165)	-	-	(43,165)
Net profit for the year ended December 31, 2024	-	-	-	-	-	1,064,721	-	-	1,064,721
Other comprehensive income (loss) for the year ended December 31, 2024, net of income tax	-	-	-	-	-	-	18,736	(2,847)	15,889
Total comprehensive income (loss) for the year ended December 31, 2024	-	-	-	-	-	1,064,721	18,736	(2,847)	1,080,610
BALANCE ON DECEMBER 31, 2024	84,725	847,249	381,924	378,623	11,384	1,998,328	7,352	(2,847)	3,622,013
Appropriation of 2024 earnings									
Legal reserve	-	-	-	102,156	-	(102,156)	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(635,437)	-	-	(635,437)
Reversal of special reserve	-	-	-	-	(11,384)	11,384	-	-	-
Changes in the Company's ownership interests in subsidiaries (Note 13)	-	-	-	-	-	(500)	-	-	(500)
Net profit for the year ended December 31, 2025	-	-	-	-	-	1,042,637	-	-	1,042,637
Other comprehensive income (loss) for the year ended December 31, 2025, net of income tax	-	-	-	-	-	-	(7,145)	1,455	(5,690)
Total comprehensive income (loss) for the year ended December 31, 2025	-	-	-	-	-	1,042,637	(7,145)	1,455	1,036,947
BALANCE ON DECEMBER 31, 2025	84,725	$ 847,249	$ 381,924	$ 480,779	$ -	$ 2,314,256	$ 207	$ (1,392)	$ 4,023,023

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	$ 1,324,444	$ 1,318,739
Adjustments for:		
Depreciation expense	461,903	408,802
Amortization expense	1,843	2,731
Expected credit loss reversed on trade receivables	(19)	-
Net loss on fair value changes of financial assets at fair value through profit or loss	61,894	100,222
Finance costs	21,394	15,697
Interest income	(62,533)	(36,248)
Dividend income	(15)	-
Share of loss of subsidiaries, associates and joint ventures	19,381	27,339
Loss on disposal of property, plant and equipment	438	5,296
Write-down of inventories	441	1,000
Net unrealized loss (gain) on foreign currency exchange	4,735	(1,155)
Gain and relief from lease modifications	(1,121)	(572)
Changes in operating assets and liabilities		
Trade receivables	28,196	7,639
Trade receivables from related parties	1,192	(1,560)
Other receivables	664	(352)
Inventories	(8,482)	(2,863)
Other current assets	(16,862)	(3,231)
Trade payables	(37,850)	(43,481)
Other payables	(9,062)	12,579
Other current liabilities	12,857	902
Cash generated from operations	1,803,438	1,811,484
Interest received	64,075	28,701
Dividends received	10	-
Interest paid	(3,954)	(3,307)
Income taxes paid	(285,995)	(270,031)
Net cash generated from operating activities	1,577,574	1,566,847
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at fair value through other comprehensive income	(848)	(113,521)
Proceeds from sale of financial assets at amortized cost	24,000	554,363
Purchase of financial assets at fair value through profit or loss	-	(1,395,595)
Payments for property, plant and equipment	(522,706)	(424,791)
Proceeds from disposal of property, plant and equipment	114	181
Increase in refundable deposits	(2,290)	(5,319)
Payments for intangible assets	(668)	(2,325)
Increase in prepayments for equipment	(36,885)	-
Net cash used in investing activities	(539,283)	(1,387,007)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	-	50,000
Proceeds from guarantee deposits received	-	40
Repayments of the principal portion of lease liabilities	(168,711)	(146,707)
Dividends paid to owners of the Company	(635,437)	(593,074)
Net cash used in financing activities	(804,148)	(689,741)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	234,143	(509,901)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	93,414	603,315
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$ 327,557	$ 93,414

The accompanying notes are an integral part of the parent company only financial statements.

Appendix 4

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Opinion

We have audited the accompanying consolidated financial statements of Universal Vision Biotechnology Co., Ltd. and its subsidiaries (collectively referred to as the "Group"), which comprise the consolidated balance sheets as of December 31, 2025 and 2024, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter for the Group’s consolidated financial statements for the year ended December 31, 2025 is described as follows:

Ophthalmology Business Division - Occurrence of Technical Service Revenue

The Group’s ophthalmology business division 2025 operating revenue - technical service revenue is the main revenue and is growing year by year, which has a significant impact on the consolidated financial statements; thus, we listed the occurrence of ophthalmology business division - technical service revenue as a key audit matter. For additional information on the accounting policy of revenue recognition, refer to Note 4.n. to the consolidated financial statements.

We have performed principal audit procedures for confirming the occurrence of the ophthalmology business division - technical service revenue as below:

1. We obtained an understanding of the design and tested the implementation effectiveness of internal control of the ophthalmology business division - technical service revenue.

2. We obtained the subsidiary ledger of the ophthalmology business division - technical service revenue and examined the contents, checked the contracts, relevant supporting documents and the collection of receivables to confirm the authenticity of the recognized technical service revenue.

Other Matter

We have also audited the parent company only financial statements of Universal Vision Biotechnology Co., Ltd. as of and for the years ended December 31, 2025 and 2024 on which we have issued an unmodified opinion.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group’s financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Wan-I Liao and Tsung-Yuan Tsai.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 5, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025		2024	
ASSETS	**Amount**	**%**	**Amount**	**%**
CURRENT ASSETS				
Cash and cash equivalents (Notes 4 and 6)	$ 779,239	13	$ 506,854	9
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	1,233,479	20	1,295,373	22
Financial assets at amortized cost - current (Notes 4, 9 and 10)	90,555	2	115,216	2
Trade receivables (Notes 4, 11 and 23)	514,490	8	565,569	10
Other receivables (Note 25)	8,820	-	11,897	-
Inventories (Notes 4 and 12)	303,628	5	289,725	5
Other current assets	71,103	1	57,187	1
Total current assets	3,001,314	49	2,841,821	49
NON-CURRENT ASSETS				
Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10)	108,744	2	111,073	2
Property, plant and equipment (Notes 4, 14 and 32)	1,905,022	31	1,756,259	31
Right-of-use assets (Notes 4 and 15)	918,315	15	917,162	16
Intangible assets (Notes 4 and 16)	6,025	-	22,790	-
Deferred tax assets (Notes 4 and 25)	73,791	1	72,259	1
Prepayments for equipment	36,885	1	-	-
Refundable deposits	42,980	1	41,202	1
Other non-current assets (Note 32)	-	-	136	-
Total non-current assets	3,091,762	51	2,920,881	51
TOTAL	$ 6,093,076	100	$ 5,762,702	100
LIABILITIES AND EQUITY				
CURRENT LIABILITIES				
Short-term borrowings (Notes 17 and 32)	$ 93,492	2	$ 92,012	2
Trade payables (Note 18)	224,365	4	268,070	5
Payables for equipment (Note 20)	81,806	1	91,080	1
Other payables (Note 19)	258,297	4	277,453	5
Current tax liabilities (Notes 4 and 25)	146,253	2	154,445	3
Lease liabilities - current (Notes 4 and 15)	184,032	3	178,399	3
Other current liabilities (Note 23)	40,747	1	29,265	-
Total current liabilities	1,028,992	17	1,090,724	19
NON-CURRENT LIABILITIES				
Deferred tax liabilities (Notes 4 and 25)	60,699	1	60,930	1
Lease liabilities - non-current (Notes 4 and 15)	785,815	13	783,828	14
Long-term accounts payable (Note 20)	57,781	1	70,908	1
Guarantee deposits	584	-	584	-
Total non-current liabilities	904,879	15	916,250	16
Total liabilities	1,933,871	32	2,006,974	35
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 22)				
Share capital				
Ordinary shares	847,249	14	847,249	15
Capital surplus	381,924	6	381,924	7
Retained earnings				
Legal reserve	480,779	8	378,623	6
Special reserve	-	-	11,384	-
Unappropriated earnings	2,314,256	38	1,998,328	35
Total retained earnings	2,795,035	46	2,388,335	41
Other equity	(1,185)	-	4,505	-
Total equity attributable to owners of the Company	4,023,023	66	3,622,013	63
NON-CONTROLLING INTERESTS	136,182	2	133,715	2
Total equity	4,159,205	68	3,755,728	65
TOTAL	$ 6,093,076	100	$ 5,762,702	100

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024	
	Amount	**%**	**Amount**	**%**
OPERATING REVENUE (Notes 4 and 23)	$ 4,204,086	100	$ 4,228,302	100
OPERATING COSTS (Notes 12 and 24)	(1,721,499)	(41)	(1,695,016)	(40)
GROSS PROFIT	2,482,587	59	2,533,286	60
OPERATING EXPENSES (Notes 11, 21 and 24)				
Selling and marketing expenses	(695,564)	(16)	(726,754)	(17)
General and administrative expenses	(409,858)	(10)	(406,181)	(10)
Expected credit gain (loss)	3,071	-	(2,444)	-
Total operating expenses	(1,102,351)	(26)	(1,135,379)	(27)
PROFIT FROM OPERATIONS	1,380,236	33	1,397,907	33
NON-OPERATING INCOME AND EXPENSES (Note 24)				
Interest income	67,532	2	39,576	1
Other income	7,801	-	8,117	-
Other gains and losses	(85,140)	(2)	(106,611)	(3)
Finance costs	(24,846)	(1)	(20,948)	-
Total non-operating income and expenses	(34,653)	(1)	(79,866)	(2)
PROFIT BEFORE INCOME TAX	1,345,583	32	1,318,041	31
INCOME TAX EXPENSE (Notes 4 and 25)	(290,984)	(7)	(267,816)	(6)
NET PROFIT FOR THE YEAR	1,054,599	25	1,050,225	25
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 4, 22 and 25)				
Items that will not be reclassified subsequently to profit or loss:				
Unrealized gain on investments in equity instruments designated as at fair value through other comprehensive income	702	-	-	-
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation of the financial statements of foreign operations	(11,427)	-	30,233	-
Unrealized gain (loss) on investments in debt instruments at fair value through other comprehensive income	942	-	(3,559)	-
Income tax relating to items that may be reclassified subsequently to profit or loss	1,598	-	(3,972)	-
Other comprehensive income (loss) for the year, net of income tax	(8,185)	-	22,702	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	$ 1,046,414	25	$ 1,072,927	25
NET PROFIT ATTRIBUTABLE TO:				
Owners of the Company	$ 1,042,637	25	$ 1,064,721	25
Non-controlling interests	11,962	-	(14,496)	-
	$ 1,054,599	25	$ 1,050,225	25
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:				
Owners of the Company	$ 1,036,947	25	$ 1,080,610	25
Non-controlling interests	9,467	-	(7,683)	-
	$ 1,046,414	25	$ 1,072,927	25
EARNINGS PER SHARE (Note 26)				
Basic	$ 12.31		$ 12.57	
Diluted	$ 12.26		$ 12.53	

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company									
							Other Equity			
	Share Capital			Retained Earnings						
	Shares (In Thousands)	Amount	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of the Financial Statements of Foreign Operations	Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	Non-controlling Interests (Note 22)	Total Equity
BALANCE ON JANUARY 1, 2024	84,725	$ 847,249	$ 381,924	$ 278,614	$ 5,042	$ 1,676,197	$ (11,384)	$ -	$ 165,333	$ 3,342,975
Appropriation of 2023 earnings										
Legal reserve	-	-	-	100,009	-	(100,009)	-	-	-	-
Special reserve	-	-	-	-	6,342	(6,342)	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(593,074)	-	-	-	(593,074)
Actual acquisition of interests in subsidiaries (Note 27)	-	-	-	-	-	(43,165)	-	-	(23,935)	(67,100)
Net profit for the year ended December 31, 2024	-	-	-	-	-	1,064,721	-	-	(14,496)	1,050,225
Other comprehensive income (loss) for the year ended December 31, 2024, net of income tax	-	-	-	-	-	-	18,736	(2,847)	6,813	22,702
Total comprehensive income (loss) for the year ended December 31, 2024	-	-	-	-	-	1,064,721	18,736	(2,847)	(7,683)	1,072,927
BALANCE ON DECEMBER 31, 2024	84,725	847,249	381,924	378,623	11,384	1,998,328	7,352	(2,847)	133,715	3,755,728
Appropriation of 2024 earnings										
Legal reserve	-	-	-	102,156	-	(102,156)	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(635,437)	-	-	-	(635,437)
Reversal of special reserve	-	-	-	-	(11,384)	11,384	-	-	-	-
Actual acquisition of interests in subsidiaries (Note 27)	-	-	-	-	-	(500)	-	-	(17,000)	(17,500)
Non-controlling interests	-	-	-	-	-	-	-	-	10,000	10,000
Net profit for the year ended December 31, 2025	-	-	-	-	-	1,042,637	-	-	11,962	1,054,599
Other comprehensive income (loss) for the year ended December 31, 2025, net of income tax	-	-	-	-	-	-	(7,145)	1,455	(2,495)	(8,185)
Total comprehensive income (loss) for the year ended December 31, 2025	-	-	-	-	-	1,042,637	(7,145)	1,455	9,467	1,046,414
BALANCE ON DECEMBER 31, 2025	84,725	$ 847,249	$ 381,924	$ 480,779	$ -	$ 2,314,256	$ 207	$ (1,392)	$ 136,182	$ 4,159,205

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	$ 1,345,583	$ 1,318,041
Adjustments for:		
Depreciation expense	541,406	518,053
Amortization expense	2,384	3,437
Expected credit loss (reversed) recognized on trade receivables	(3,071)	2,444
Net loss on fair value changes of financial assets at fair value through profit or loss	61,894	100,222
Finance costs	24,846	20,948
Interest income	(67,532)	(39,576)
Dividend income	(15)	-
Loss on disposal of property, plant and equipment	602	7,464
Costs transferred from property, plant, and equipment to expenses	-	1,332
Loss on disposal of intangible assets	16	1,452
Write-down of inventories	-	2,965
Impairment loss of Intangible assets	16,171	-
Reversal of write-down of inventories	(13)	-
Net unrealized loss (gain) on foreign currency exchange	4,735	(1,155)
Gain and relief from lease modifications	(1,121)	(572)
Changes in operating assets and liabilities		
Trade receivables	54,316	16,103
Other receivables	628	(390)
Inventories	(13,836)	1,800
Other current assets	(13,916)	4,595
Trade payables	(43,705)	(44,238)
Other payables	(19,196)	16,499
Other current liabilities	11,482	146
Cash generated from operations	1,901,658	1,929,570
Interest received	69,136	31,080
Dividends received	10	-
Interest paid	(5,260)	(5,048)
Income taxes paid	(299,105)	(283,536)
Net cash generated from operating activities	1,666,439	1,672,066
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at fair value through other comprehensive income	(848)	(113,521)
Proceeds from sale of financial assets at amortized cost	22,904	463,147
Purchase of financial assets at fair value through profit or loss	-	(1,395,595)
Payments for property, plant and equipment	(525,772)	(434,646)
Proceeds from disposal of property, plant and equipment	114	863
Increase in refundable deposits	(2,071)	(2,808)
Payments for intangible assets	(1,164)	(2,446)
Decrease in other non-current assets	131	-
Increase in prepayments for equipment	(36,885)	-
Decrease in prepayments for equipment	-	878
Net cash used in investing activities	(543,591)	(1,484,128)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	48,607	82,524
Repayments of short-term borrowings	(46,361)	-
Repayments of long-term borrowings	-	(1,353)
Proceeds from guarantee deposits received	-	40
Repayments of the principal portion of lease liabilities	(204,534)	(184,076)
Dividends paid to owners of the Company	(635,437)	(593,074)
Acquisition of additional interests in subsidiaries	(17,500)	(67,100)
Changes in non-controlling interests	10,000	-
Net cash used in financing activities	(845,225)	(763,039)
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES	(5,238)	19,410
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	272,385	(555,691)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	506,854	1,062,545
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$ 779,239	$ 506,854

The accompanying notes are an integral part of the consolidated financial statements.

Appendix 5

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

2025 Statement of the Distribution of Earnings

Unit: NT$

Item	Amount	
Beginning undistributed earnings		$1,272,119,269
Plus: Net profit after tax for the period		1,042,637,366
Less: Retained earnings adjusted due to investments accounted for using equity method (Note 1)		(499,882)
Less: Legal reserve allocation（10%）		(104,213,748)
Less: Special reserve allocation		(1,184,913)
Distributable earnings for the period		$2,208,858,092
Distributable items (Note 2)		
Common share - cash dividend (NT$7.75 per share)	($656,617,968)	(656,617,968)
Ending undistributed earnings		$1,552,240,124

Note 1: Retained earnings adjusted due to the debit balance incurred from the change in shareholding ratio (without influencing control or without significant impact).

Note 2: The undistributed earnings in 2025 were prioritized for this distribution of earnings; and the dividend amount is calculated based on the current number of shares, which is 84,724,899 shares.

Chairperson: Ou Shu-Fang

General Manager: Lu Kenneth

Accounting Manager: Sun Yu-Chiao